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PROFORMA 
 
CARDIAC FUNCTIONS IN ALCOHOLIC AND NON - ALCOHOLIC 
CIRRHOSIS 
 
Case No :  Name :   Age :   Sex : 
 
Occupation:  Address:   IP No.: 
 
Height :  Weight : 
 
Alcoholism : Y/N Type :  Amount : D/W Duration : 
 
Habits : Smoking / drug addiction  
 
Bleeding  : Haematemesis / Melena / Per rectum 
 
Abdominal distension  Pedal Edema 
 
Treatment History : 
 
General Examination : 
Anemia Jaundice Cyanosis Clubbing LNE 
P/R-  /mt  B.P.  mm Hg 
 
CVS : 
 JVP 
 Apical Impulse 
 Pulsations : 
  LP  Epigastric  Second LICS 
 S1 S2  Addtl. Sounds  Murmur 
 
 
GIT : 
 Distension   Dilated veins 
 Liver   Spleen Fluid thrill Shifting dullness 
 Bowel sounds Bruit 
 
R/S 
 Breath sounds  Added sounds 
 
CNS  
 Higher functions  Sensory system 
 Cerebellar signs  Motor system 
 
Investigations 
Hb  TC   DC  ESR  Platelet count 
Urine  Albumin  Sugar  Deposits 
RBS  Blood Urea  S. Creatinine 
ECG 
 
ECHOCARDIOGRAPHY 
TR Jet velocity - m/s Gradient - mm Hg PAH– Mild/Mod/Severe 
 
Systolic function indices : 
IVSd  LVPWd LVIDd 
IVSs  LVPWs LVIDs 
EF- % LV Mass 
 
Diastolic function indices: 
IVRT  Mitral E- m/s A- m/s E/A- 
  Tricuspid E- m/s A- m/s E/A- 
 
Deceleration Time (DT): 
 
Pulmonary venous Doppler - S - D- AR- 
USG Abdomen : 
 
S. bilirubin T- D- Total protein- Albumin- Globulin- 
SALP  SGOT  SGPT 
 
OGD- 
 
Viral Markers- 
 
 
 1
INTRODUCTION 
 
Cirrhosis is associated with a spectrum of characteristic clinical 
manifestations. Clinical features of cirrhosis derive from the morphologic 
alterations and often reflect the severity of hepatic damage rather than the 
etiology of the underlying liver disease1. 
 
Loss of functioning hepatocellular mass may lead to jaundice, edema, 
coagulopathy and a variety of metabolic abnormalities: Fibrosis and distorted 
vasculature leads to portal hypertension and its sequelae, including gastro-
esophageal varies and splenomegaly1. 
 
Involvement of the cardiovascular system is crucial during the course 
of cirrhosis due to its pathophysiological, clinical and therapeutic 
relationships with the liver. 
 
Cardiovascular alterations are frequently observed in the late stages 
of cirrhosis. It may result in subclinical latent cardiomyopathy with 
hyperdynamic circulation characterised by increased cardiac output and 
decreased peripheral resistance. The pathogenesis of these hemodynamic 
alterations is still uncertain2. 
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It was previously reported that chronic alcoholism may have an effect 
on heart3. Hence, it is worth comparing the cardiac parameters between 
alcoholic and non-alcoholic cirrhosis. 
 
The cardiovascular changes should be taken into serious 
consideration during programming of therapy for the complications of 
cirrhosis, in particular ascites (diuretic treatment, paracentesis, Le Veen 
peritoneo – venous shunt) and portal hypertension. 
 
A stable cardiac status is important before the performance of 
interventional procedures or liver transplantation. Perioperative cardiac 
dysfunction has been observed in upto 50 percent of patients after 
transplantation4, with overt heart failure occurring in 1 percent to 2 percent 
of patients4,5. Some reports have suggested that this cardiac dysfunction 
may be reversible5. However, cardiac failure is a cause of mortality in upto 7 
percent to 20 percent of transplants recipients 6,7. Hence it is relevant to 
perform a detailed study of cardiovascular system in cirrhosis patients. 
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OBJECTIVES OF THE STUDY 
 
1. To assess the cardiac functions of alcoholic and non – alcoholic 
cirrhosis patients and controls. 
 
2. To compare the cardiac functional status between alcoholic and 
non-alcoholic cirrhosis patients. 
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REVIEW OF LITERATURE 
 
Definition 
 Cirrhosis is defined pathologically as a diffuse process with fibrosis 
and nodule formation. Although the causes are many, the end results are 
the same.8 
 
Evolution of Cirrhosis9 
 The responses of the liver to necrosis are limited; the most important 
are collapse of hepatic lobules, formation of diffuse fibrous septae and 
nodular regrowth of liver cells. Fibrosis follows hepatocellular necrosis. 
Nodules, which disturb the hepatic architecture follow cell death and full 
cirrhosis develops. 
 
Fibrogenesis 
 The transformation of normal liver to a fibrotic liver and eventually 
cirrhosis is a complex process involving several key components, in 
particular stellate cells, cytokines, proteinases and their inhibitors.  
 
 The hepatic stellate cell (also called lipocyte, fat storing cell, Ito cell, 
pericyte) is the principal cell involved in fibrogenesis. Imbalance between 
matrix synthesis and degradation plays a major role in hepatic fibrogenesis. 
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With continued alcohol intake and destruction of hepatocytes, fibroblasts 
appear at the site of injury and deposit collagen. Web like septae of 
connective tissue appear in periportal and pericentral zones and eventually 
connect portal triads and central veins. This fine connective tissue network 
surrounds small masses of remaining liver cells, which regenerate and form 
nodules. With continuing hepatocyte destruction and collagen deposition, 
the liver shrinks in size, and acquires a nodular appearance as end-stage 
cirrhosis develops.9 
 
Classification of cirrhosis9 
 Three anatomical types of cirrhosis are recognised micro nodular, 
macro nodular and mixed. Micronodular cirrhosis is characterised by thick 
regular septae, by regenerating small nodules varying little in size, and by 
involvement of every lobule. The macronodular liver may represent impaired 
capacity for regrowth as in alcoholism, malnutrition, old age or anaemia. 
Regeneration in a micronodular cirrhosis results in a macronodular or mixed 
appearance. With time, micronodular cirrhosis often converts to 
macronodular. 
 
Aetiology9 
 Viral hepatitis type B + delta; C 
 Alcohol 
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 Metabolic, e.g. haemochromatosis, Wilson’s disease, α1- 
antitrypsin deficiency, type IV glycogenosis, galactosemia, 
congential tyrosinosis and non-alcoholic steatohepatitis. 
 Prolonged cholestasis, intra and extra – hepatic. 
 Hepatic venous outflow obstruction, e.g. venoocculsive disease, 
Budd-Chiari syndrome, constrictive pericarditis. 
 Disturbed immunity (autoimmune hepatitis) 
 Toxins and therapeutic agents, eg. Methotrexate, amiodarone. 
 Indian childhood cirrhosis 
 Cryptogenic cirrhosis 
 
Diagnosis of Cirrhosis9 
 
Clinical History 
 Fatigue and weight loss, loss of libido, anorexia and flatulent 
dyspepsia, abdominal pain, colour of urine and faeces, swelling of legs or 
abdomen, haemorrhage – nose, gums, skin, alimentary tract. Past health : 
jaundice, hepatitis, drugs ingested, blood transfusion. Social : alcohol 
consumption. 
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Examination 
 Nutrition, fever, fetor hepaticus, jaundice, pigmentation, purpura, 
clubbing, white nails, vascular spider, palmar erythema, gynaecomastia, 
testicular atrophy, distribution of body hair. 
 
Abdomen  
Ascites, abdominal wall veins, liver, spleen, oedema. 
 
Neurological changes  
Mental functions, stupor, tremor 
 
Investigations 
Haematology 
∆ Haemoglobin     
∆ Platelet count 
∆ Leucocyte count    
∆ Prothrombin time 
 
Serum biochemistry 
∆ Bilirubin     
∆ Alkaline Phosphatase 
∆ Transaminases    
∆ γ- glutamyl transpeptidase (γ - GT) 
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∆ Immunoglobulins   
∆ Albumin and globulin 
 
If ascites present 
∆ Serum electrolytes   
∆ Daily weight 
∆ Urea and creatinine   
∆ 24 hours urinary volume and sodium 
 
Serum immunological investigations 
∆ Hepatitis B Ag, Anti HCV 
∆ Alpha fetoprotein 
∆ Smooth muscle, mitochondrial, nuclear antibodies 
 
Endoscopy 
 
Hepatic CT scan or ultrasound 
 Using ultrasound, cirrhosis is suggested by fine surface nodularity and 
portal vein mean flow velocity. The caudate lobe is enlarged relative to the 
right lobe. Regeneration nodules may be shown as focal lesions. CT scan is 
cost – effective for the diagnosis of cirrhosis and its complications. Liver size 
can be assessed and the irregular nodular surface seen. After intravenous 
contrast, the portal vein and hepatic veins can be identified in the liver, and 
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a collateral circulation with splenomegaly may give confirmation to the 
diagnosis of portal hypertension. Ascites can be seen. 
 
Laparotomy 
 Laparotomy should never be used to diagnose cirrhosis because it 
may precipitate liver failure even in those with very well compensated 
disease. 
 
Laparoscopy 
 Laparoscopy visualizes the nodular liver and allows directed liver 
biopsy. 
 
Liver biopsy 
 Biopsy diagnosis of cirrhosis may be difficult. Reticulin and collagen 
stains are essential for the demonstration of a rim of fibrosis around the 
nodule. 
 
EEG 
 EEG indicated if neuropsychiatric changes are present and to detect 
early changes in pre coma. 
 
Clinical and pathological associations9 
∆ Nutrition : Protein – calorie malnutrition is commonly seen in 
chronic liver disease, present in 20% of patients with 
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compensated cirrhosis and more than 60% of those with severe 
hepatic dysfunction. Malnutrition also is an independent predictor 
for the first variceal bleed and survival in patients with 
oesophageal varices. 
∆ Parotid gland enlargement and Dupuytren’s contracture are seen 
in some alcoholic patients with cirrhosis. 
∆ Digital clubbing and hypertrophic oesteroarthropathy may be seen 
in cirrhosis, especially biliary cirrhosis. 
∆ Muscle cramps occur significantly more frequently in cirrhotic 
patients and correlated with the presence of ascites, low mean 
arterial pressure. 
∆ Steatorrhoea is frequent due to reduced hepatic bile salt secretion 
even in the absence of  pancreatitis or alcoholism. 
∆ Splenomegaly and abdominal wall venous collaterals usually 
indicate portal hypertension. 
∆ Abdominal herniae are common with ascites. 
∆ Gastrointestinal: Peptic ulceration has been found in cirrhosis 
more frequently than in those who are HBsAg positive. Duodenal 
ulcers were more frequent than gastric ulcers. 
∆ Primary liver cancer is frequent with all forms of cirrhosis except 
the biliary and cardiac types with an overall 60-fold increased risk. 
∆ Cardiovascular: Cirrhotics are less liable to coronary and aortic 
atheroma. Cirrhosis is associated with an increased cardiac output 
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and heart rate, decreased systemic peripheral vascular resistance 
and blood pressure. Cirrhotic cardiomyopathy is recognised with 
abnormal cardiac contractility. 
∆ Pulmonary: Hypoxemia may be due to the hepatopulmonary 
syndrome and right heart failure due to porto pulmonary 
hypertension. α1- Antitrypsin deficiency may cause childhood liver 
disease, and later emphysema and silent cirrhosis. 
∆ Renal: Changes in intrarenal circulation, and particularly a 
redistribution of blood flow away from the cortex, are found in all 
forms of cirrhosis. This predisposes to the hepato-renal syndrome. 
∆ Infections: Bacterial infections are frequent due to reduced 
immune defence mechanisms and impaired reticuloendothelial cell 
phagocytic activity. Patients with ascites are prone to spontaneous 
bacterial peritonitis (SBP). Sepsis should always be suspected in 
cirrhotic patients with unexplained pyrexia or deterioration. After 
gastrointestinal haemorrhage the risk of sepsis is greater in Child 
C rather than Child A/B grade cirrhotics. There is increased 
occurrence of tuberculosis, in cirrhotics and tuberculous peritonitis 
is therefore still encountered but often not suspected. 
∆ Diabetes Mellitus: While upto 80% of cirrhotics are glucose 
intolerant, only 10-20% are truly diabetic. 
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Compensated cirrhosis9 
 The disease may be discovered at a routine examination or 
biochemical screen, or at operation undertaken for some other condition. 
Cirrhosis may be suspected if the patient has mild pyrexia, vascular spiders, 
palmar erythema, or unexplained epistaxis or oedema of the ankles. Firm 
enlargement of the liver and splenomegaly are helpful diagnostic signs. 
Vague morning indigestion and flatulent dyspepsia may be early features in 
the alcoholic cirrhotic. Confirmation should be sought by biochemical tests, 
scanning and if necessary, by liver biopsy. Biochemical tests may be quite 
normal in this group. The most frequent changes are a slight increase in the 
serum transaminase or γ– GT level. Diagnosis is confirmed by needle biopsy 
of liver. 
 
Decompensated Cirrhosis 
 The patient usually seeks medical advice because of ascites and or 
jaundice. General health fails with weakness, muscle wasting and weight 
loss. Continuous mild fever (37.5-380C) is often due to gram-negative 
bacteremia, continuing hepatic cell necrosis or liver cell carcinoma. A liver 
flap may be present. The deeper the jaundice, the greater the liver cell 
dysfunction. 
 
 Pigmentation of the skin and clubbing of the fingers are occasionally 
seen. Purpura over the arms, shoulders and shins may be associated with a 
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low platelet count. Spontaneous bruising and epistaxis reflect a  prothrombin 
deficiency. The blood pressure is low. Sparse body hair, vascular spiders, 
palmar erythema, white nails and gonadal atrophy are common. Ascites and 
oedema of the legs are frequently associated. The liver may be enlarged 
(early  stages), with a firm regular edge, or contracted and impalpable (late 
stages). The spleen may be palpable. 
 
Laboratory findings 
 
Haematology 
There is usually a mild normocytic, normochromic anaemia; it is 
occasionally macrocytic. Gastrointestinal bleeding leads to hypochromic 
anaemia. The leucocyte and platelet counts are reduced (‘hypersplenism’). 
The prothrombin time is prolonged and does not return to normal with 
vitamin K therapy. The bone marrow is macro normoblastic. 
 
Serum biochemical changes 
In addition to the raised serum bilirubin level, albumin is depressed 
and γ–globulin raised. The serum alkaline phosphatase is usually raised to 
about twice normal; very high readings are occasionally found, particularly 
with alcoholic cirrhosis. Serum transaminase values may be increased. 
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Urine 
Urobilinogen and bilirubin are detected if the patient is jaundiced. 
 
Needle biopsy diagnosis 
 This may give a clue to the aetiology and inflammatory activity. If 
there are contraindications, such as ascites or a coagulation defect, the 
transjugular approach should be used. 
 
Child Pugh Classification9 
Points 
 1 2 3 
Encephalopathy (grade) None  1 – 2 3 – 4 
Ascites Absent Slight Moderate–Severe 
Bilirubin (mg/dl) <2 2 – 3 > 3 
Albumin (g/dl) >3.5 2.8 – 3.5 < 2.8 
Prothrombin time  
(sec prolonged) 
<4 4 – 6 > 6 
INR <1.7 1.7 – 2.3 >2.3 
 
 The total score classified patients into grade A (5-7) B (7-9) or C 
(>10). Poor prognosis is associated with a prolonged prothrombin time, 
marked ascites, gastrointestinal bleeding, advanced age, high daily alcohol 
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consumption, high serum bilirubin and alkaline phosphatase, low albumin 
values, and poor nutrition. Patients with compensated cirrhosis become 
decompensated at the rate of 10% per year. Ascites is the usual first sign. 
Decompensated patients have around a 20% 5 year survival. 
 
The following points are useful prognositically: 
• Liver size: A large liver carries a better prognosis than a small one 
because it is likely to contain more functioning cells. 
• Haemorrhage from oesophageal varices: If liver function is good, 
haemorrhage may be tolerated; if poor, hepatic coma and death 
are probable. 
• Persistent hypotension (systolic BP < 100 mm-Hg) is serious. 
• Ascites worsens the prognosis. 
• If decompensation has followed haemorrhage, infection or 
alcoholism, the prognosis is better than if it is spontaneous, 
because the precipitating factor is correctable. 
• Jaundice, especially if persistent, is a serious sign. 
• Neurological complication. The significance of encephalopathy 
depends on clinical circumstances. Developing in the course of 
progressive hepatocellular failure, it carries a bad prognosis. 
Chronic and those with an extensive portal – systemic collateral 
circulation who respond well to medical treatment carries good 
prognosis. 
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• Biochemical tests: If the serum albumin is less than 25g/l the 
outlook is poor. Hyponatremia (serum sodium < 120 mmol/l), if 
unrelated to diuretic therapy, is grave. Serum transaminase and 
globulin levels give no guide to prognosis. 
• Alcoholic cirrhotics, if they abstain, respond better than those with 
‘cryptogenic’ cirrhosis. 
• The response to therapy: If the patient has failed to improve 
within 1 month of starting hospital treatment, the outlook is poor. 
• Hepatic histological changes: Section are useful in evaluating the 
extent of necrosis and of inflammatory infiltration. A fatty liver 
responds well to treatment. 
 
CIRRHOSIS AND CARDIOVASCULAR INVOLVEMENT 
 
 Cardiovascular alterations are frequently observed in the late stages 
of cirrhosis. The patient with hepatocellular dysfunction in cirrhosis shows 
marked vasodilatation accompanied by hyperdynamic circulation and 
opening of arteriovenous shunts2. The effect of these circulatory changes 
and especially the profound vasodilatation has only recently been 
investigated in detail1,2. 
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Hyperdynamic Circulatory State 
 Systemic hemodynamic alterations have been recognised in patients 
with chronic liver disease and may occur in more than 30 percent of 
cirrhotics 10,11. This hyperdynamic circulatory state is characterised by 
splanchnic and systemic vasodilatation and an elevated cardiac output. 
Clinically, patients may present with low blood pressure, tachycardia, and a 
cardiac flow murmur. Cutaneous stigmata of vasodilatation in chronic liver 
disease including spider angiomata and palmar erythema may also be 
present. The usefulness of cutaneous findings in predicting the presence or 
absence of a hyperdynamic state is unknown. When measured, cardiac 
output is elevated and systemic vascular resistance is low. The clinical and 
hemodynamic alterations in the hyperdynamic circulatory state of cirrhosis 
are similar to those seen in endotoxemia and sepsis. This observation 
contributed to the initial hypothesis by Vallance and Moncada that endotoxin 
and cytokine mediated nitric oxide production contributes to the 
hyperdynamic circulation in cirrhosis 12. In addition, it is now increasingly 
recognised that the vascular alterations associated with the hyperdynamic 
circulatory state may also occur in other organs and contribute to 
pulmonary, renal and central nervous system complications seen in liver 
disease.13  
 
 The pathogenesis of cardiovascular complications in chronic liver 
disease remains an area of intense study. Significant experimental data have 
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implicated excess nitric oxide production as a major contributor to the 
splanchnic and systemic vasodilatation underlying the hyperdynamic 
circulatory state 14,15. The majority of information suggests that nitric oxide 
production is generated from the endothelial form of nitric oxide synthase 
found in the vasculature rather than from the inducible form of nitric oxide 
synthase found more commonly in parenchymal, smooth muscle, and 
inflammatory cells, as originally hypothesized 12. This concept has recently 
been supported by experimental work demonstrating that mediators, 
classically known to up-regulate inducible nitric oxide synthase, also 
modulate endothelial nitric oxide synthase, in experimental cirrhosis 16. 
However, the pathogenesis of the hyperdynamic circulatory state is likely 
multi-factorial and other mediators, including glucagon, prostaglandins and 
bile acids may contribute to vasodilatation 17. Vasodilatation is accompanied 
by sodium and water retention and leads to total body fluid overload and an 
elevated cardiac output. However, the primary stimulus for vascular nitric 
oxide production remains unknown. 
 
 The relative importance of hepatic dysfunction and portal 
hypertension in triggering the hyperdynamic circulatory state is also 
unknown. Although the hyperdynamic circulatory state is generally more 
pronounced in more severe liver disease18, a similar state is seen in 
experimental animals14 and in humans20 with extrahepatic portal 
hypertension. These findings suggest that both hepatic dysfunction and 
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portal hypertension may trigger changes in the splanchnic and systemic 
vasculature leading to nitric oxide overproduction. The observation that the 
hyperdynamic circulatory state worsens for a period of at least 1 to 3 
months after portal pressure is acutely lowered by transjugular intrahepatic 
portosystemic shunt (TIPS)21 suggests that the interactions between portal 
pressure, hepatic synthetic function and portosystemic shunting that lead to 
the hyperdynamic circulatory state are complex. 
 
Cirrhotic Cardiomyopathy 
 Shortly after the recognition of the hyperdynamic circulatory state in 
liver disease, studies suggested that the cardiac response during increased 
demand was subnormal in cirrhosis 22. Initial studies were performed in 
alcoholic cirrhosis 23, 24 and led to the assumption that alcohol was the cause 
of the cardiac dysfunction. More recently, it has been established that the 
cardiac response to physiologic and pharmacologic stresses may be impaired 
in many different types of cirrhosis. This finding has resulted in the 
recognition that a unique form of high output cardiac dysfunction occurs in 
liver disease 22. Clinically, cardiac dysfunction is often mild or latent in 
cirrhosis, a finding some have attributed to the after load reducing effects of 
systemic vasodilatation that decrease cardiac work22. However, in the setting 
of increased cardiac stress such as liver transplantation 4,25 and TIPS, 21 
overt cardiac dysfunction may occur. Perioperative cardiac dysfunction has 
been observed in upto 50 percent of patients after transplantation 4, with 
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overt heart failure occurring in 1 percent to 2 percent of patients 4,5. Some 
reports have suggested that this cardiac dysfunction may be reversible5. 
However, cardiac failure is a cause of mortality in upto 7 percent to 20 
percent of transplant recipients1,7. No studies have identified reliable 
screening methods to define which patients have latent cardiac dysfunction 
and may be at risk for overt heart failure under stress26. 
 
 The pathogenesis of the cardiac dysfunction in liver disease has 
largely been investigated in experimental models and likely involves a 
number of abnormalities. Alterations in cardiac β– adrenergic signaling 27-29, 
decreased plasma membrane fluidity29, increased cardiac nitric oxide 
production30-31 and elevated circulating levels of catecholamines32 have all 
been suggested to contribute to cardiac dysfunction. However, how these 
abnormalities relate to the hyperdynamic circulatory state and the degree of 
hepatic synthetic dysfunction and whether similar abnormalities contribute to 
human disease remain unknown. The pathophysiologic mechanisms in 
alcoholic cardiomyopathy appear to be different from cirrhotic 
cardiomyopathy33, supporting the idea that the two entities are distinct. In 
addition, the common perception that alcoholic cardiomyopathy is infrequent 
in alcoholic cirrhosis appears to be incorrect, because the two entities 
commonly co-exist3. Finally, genetic hemochromatosis may also result in the 
development of a dilated cardiomyopathy secondary to iron mediated 
myocardial injury34. 
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Pulmonary Complications 
 Pulmonary symptoms and abnormalities occur commonly in patients 
with chronic liver disease. As many as 70 percent of cirrhotic patients 
undergoing evaluation for liver transplantation, if asked, complain of 
dyspnoea35. Arterial blood gas and pulmonary function abnormalities also 
are common and are found in as many as 45 percent to 50 percent of 
patients36. A variety of causes for pulmonary dysfunction in liver disease 
have been identified and include intrinsic cardiopulmonary disorders not 
specifically related to liver disease and unique problems associated with the 
presence of liver disease or portal hypertension. The recognition that a 
subset of patients with hepatic disease develop significant pulmonary 
vascular alterations, either microvascular dilation leading to the hepato 
pulmonary syndrome (HPS) or arteriolar vasoconstriction leading to 
portopulmonary hypertension, indicates that unique changes in the 
pulmonary vasculature may occur in liver disease. These pulmonary vascular 
syndromes significantly impact morbidity and mortality in affected patients 
and may influence candidacy for liver transplantation. 
 
Hepatopulmonary syndrome 
 HPS result from intrapulmonary microvascular dilation that occurs in a 
subgroup of patients with liver disease or portal hypertension. It is 
commonly defined by the presence of hepatic dysfunction or portal 
hypertension, a widened age corrected alveolar arterial oxygen gradient on 
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room air with or without hypoxemia, and intra pulmonary vasodilation11. 
Presently, studies demonstrate that as many as 40 percent of cirrhotic 
patients have detectable intrapulmonary vasodilatation38 and that upto 8 to 
15 percent will develop impaired oxygenation leading to significant 
functional limitations 37. 
 
 The pathogenesis of intrapulmonary vasodilatation in HPS is an area 
of active investigation. Studies in humans have implicated enhanced 
pulmonary production of nitric oxide in the development of vasodilatation by 
assessing exhaled nitric oxide production39. However, the cause of the 
increased pulmonary nitric oxide production and its relationship to the 
presence of portal hypertension, the hyperdynamic circulation, and the 
degree of liver injury remains undefined. Animal studies suggest that low 
level production and release of endothelin – 1 during liver injury may 
increase the levels and activity of pulmonary vascular endothelial nitric oxide 
synthase in the setting of portal hypertension, which leads to excess local 
nitric oxide production and vasodilatation40. However, whether hepatic 
endothelin – 1 production contributes to the development of human disease 
is unknown. 
 
Portopulmonary Hypertension 
 The association between pulmonary artery hypertension and portal 
hypertension has been termed ‘portopulmonary hypertension’. It is defined 
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by the National Institute of Health Patient Registry for the characterisation of 
primary pulmonary hypertension as a mean pulmonary artery pressure 
greater than 25 mm Hg and a pulmonary capillary wedge pressure lower 
than 15 mm Hg in the setting of portal hypertension41. 
 
 Portopulmonary hypertension frequently presents with progressive 
symptoms that may begin as non specific complaints of fatigue, dyspnea, 
and peripheral edema. The severity of these symptoms worsens with 
increasing pulmonary hypertension42. However, similar symptoms are 
common in cirrhosis without pulmonary hypertension and are also seen in 
HPS. 
 
 The prevalence and severity of portopulmonary hypertension do not 
appear to correlate with the degree of hepatic synthetic dysfunction; azygos 
blood flow, or the severity of portal hypertension. However, survival in 
pulmonary hypertension correlates with the severity of right-sided cardiac 
dysfunction as assessed by the degree of elevation in the right atrial 
pressure and the degree of decline in the cardiac output. Accordingly, 
survival appears to be prolonged in portopulmonary hypertension relative to 
primary pulmonary hypertension (5 year survival, 50 present versus 25 
percent), possibly related to the beneficial effects of the hyperdynamic 
circulatory state. Nonetheless, portopulmonary hypertension is generally 
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progressive and has a high likelihood of contributing to morbidity and 
mortality in affected cirrhotics42. 
 
 The pulmonary histologic abnormalities in portopulmonary 
hypertension are identical to those found in primary pulmonary hypertension 
and include smooth muscle proliferation and hypertrophy, concentric intimal 
fibrosis, plexogenic arteriopathy and necrotizing vasculitis. The cause of 
these abnormalities remains incompletely understood. 
 
 Studies that have evaluated the diagnostic utility of various clinical 
predictors of portopulmonary hypertension including systemic hypertension, 
accentuated P2, echocardiographic measurement of pulmonary artery 
pressures and right  ventricular dilation, and electrocardiographic and chest 
radiographic abnormalities have shown that these predictors are in general 
specific but of low sensitivity. Many transplant centers will routinely perform 
echocardiography in transplant candidates more than 40 years of age and 
proceed to right heart catheterization if the estimated pulmonary arterial 
pressure is greater than 50 mm Hg or when right ventricular dilation or 
hypertrophy is present42. 
 
L-carnitine, cirrhosis of liver and cardiac involvement 
 L-carnitine is an essential co-factor in the transfer of long chain fatty 
acids across the inner mitochondrial membrane for oxidation. Fatty acids 
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have an important role in myocardial metabolism. There have been previous 
reports that deficiency of L-carnitine may have an effect on myocardial fatty 
acid metabolism and subsequent development of dilated cardiomyopathy43. 
Since L-carnitine levels and metabolism were altered in cirrhosis, it may 
contribute to cardiac dysfunction.   
 
INVESTIGATIONS FOR ASSESSING CARDIAC INVOLVEMENT47 
 The assessment of left ventricular function is an essential component 
of the evaluation of any patient with suspected heart disease. 
Echocardiography is an excellent tool for non –invasive assessment of left 
ventricle. 
 
Intracavity dimensions 
 Measurements can be made on an M-mode (motion mode) 
echocardiogram during diastole (d) and systole (s). (Figure 1). These 
measurements reflect the chamber dimensions of the heart. 
 
 All M mode measurements be made from leading edge to leading 
edge. From M mode measurements taken at the tip of the mitral valve level 
in parasternal long axis view, ejection fraction can be measured. Ejection 
fraction represents the percent or fractions of left ventricular diastolic 
volume that is ejected in systole. 
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LV Diastolic function 
 Spectral Doppler is currently the technique of choice for evaluating 
left ventricular diastolic functions. 
 
 Figure 2 illustrates the left ventricular inflow velocities and 
measurements for assessing the diastolic function of the left ventricle. Figure 
2(A) shows the normal situation. The early inflow of blood reaches a peak at 
the E point. Flow then decelerates until atrial systole, at which time the left 
atrial pressure rises above the left ventricular pressure and flow again 
passes through the mitral valve. 
 
 Alterations in left ventricular diastolic function may reduce the height 
of the E wave and increase the height of the ‘A’ wave. This type of 
abnormality is usually accompanied by prolongation of the isovolumic 
relaxation time (IVRT) and prolongation of the decelaration time (DT). 
[Figure 2 (B)] The hemodynamic abnormalities responsible for this pattern 
usually are reduced left ventricular relaxation and slower fall in left 
ventricular pressure. 
 
 The other pathologic pattern that is seen with mitral flow velocities is 
the reverse – a tall E wave and a short A wave. This pattern is accompanied 
by short isovolumic relaxation and deceleration times. [Figure 2 (D)] This 
type of mitral inflow can be produced by elevated left ventricular filling 
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pressures. With elevated early diastolic pressure, the flow into the left 
ventricle is accelerated and there may be relatively little blood to propel with 
atrial systole. 
 
 In some disease states, the initial pathologic pattern in abnormal 
relaxation with a short E wave and tall A wave. If mitral regurgitation or 
congestive heart failure raises the left ventricular filling pressure, then the 
pattern may reverse and the E wave will become taller and A wave will 
become shorter. Thus a transition situation can occur whereby 
‘pseudonormalisation’  of the mitral inflow can occur. [Figure 2 (C)] 
 
 Pulmonary venous flow also reflects changes in left ventricular 
diastolic function. With reduced early relaxation, the diastolic component 
decreases and the reversed ‘A’ wave increases. When early filling is rapid, 
the pulmonary venous flow exhibits almost no systolic phase and tall 
diastolic and atrial components. 
 
Estimation of the systolic pressure in pulmonary artery (PA) 
 This measurement can be done using modified Bernoulli equation. 
With the transducer in the apical position, tricuspid regurgitation jet velocity 
is measured. Pressure gradient is given by the modified Bernoulli equation 
∆P = 4V2  in which V is the peak velocity of the tricuspid regurgitation jet. 
PA systolic pressure is calculated by adding ten to the estimated pressure 
gradient. 
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MATERIALS AND METHODS 
 
1. Type of Study   : Prospective Observational  
Analytical Study 
 
2. Place    : Government Rajaji Hospital,  
Madurai 
 
3. Collaborating Departments : Department of Medical  
Gastroenterology and Department of 
Cardiology. 
 
4. Duration of Study  : June 2004 to May 2005 
 
5. Ethical clearance  : Ethical clearance was obtained and 
the study was initiated 
 
6. Consent    : Informed consent was obtained  
before taking up the case for study 
 
7. Inclusion Criteria 
 All newly diagnosed cases of cirrhosis of liver based on physical 
examination, biochemical parameters, ultrasonogram of abdomen and upper 
GI endoscopy. 
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8. Exclusion Criteria 
∆ Age < 20 years and > 60 years 
∆ Sex : Female 
∆ CVS  
o Systemic arterial hypertension 
o Primary cardiac / pulmonary diseases 
o Hemodynamic instability 
∆ GIT 
o Hepatic encephalopathy 
o Gross ascites 
o Viral hepatitis 
∆ Haematological 
o Anemia 
∆ Metabolic 
o Diabetes Mellitus 
o Thyroid dysfunction 
∆ Active infection / Septicemia 
∆ Collagen vascular diseases 
∆ Malignancies 
∆ Habits 
o Smoking 
o Drug addiction  
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∆ Drugs 
o Hepatotoxic drug intake 
o Cardiac drug intake 
∆ Un co-operative patients 
 
9. Materials : 
 A total of one hundred consecutive adult male patients of cirrhosis of 
liver, admitted to the medical and gastroenterology wards of Government 
Rajaji Hospital, Madurai were selected based on inclusion and exclusion 
criteria. 
 
 All patients in the study underwent full clinical evaluation. Clinical 
history and physical examination findings were recorded with particular 
attention to present or previous haematemesis, melena, bleeding PR, other 
bleeding tendencies, alcoholism, blood transfusion, intake of hepatotoxic 
drugs, jaundice, anemia, edema, stigmata of chronic liver disease, dilated 
abdominal veins, splenomegaly, ascites and encephalopathy. 
 
 All patients were subjected to the following haematological, 
biochemical and microbiological studies. 
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Blood 
∆ Hb, TC, DC, ESR  
∆ Platelet count 
∆ Random blood sugar 
∆ Blood urea and serum creatinine 
∆ Liver function tests 
o Serum bilirubin (total and direct) 
o Total protein, albumin and globulin 
o Serum alkaline phosphatase 
o ALT and AST 
∆ Viral markers 
 
 Each one of them was subjected to ultrasonogram of abdomen to 
confirm the presence of cirrhosis. Upper GI endoscopy was done in all 
patients, after overnight fasting early in the morning. Single channel electro 
cardiogram (using Alpha 99 trans health care) was done to measure the 
electrical activity of the heart. Colour Doppler Echocardiogram (using Aloka, 
Philips system) was done to assess the cardiac involvement. The parameters 
studied were : 
 
o Systolic function indices 
 Left ventricular internal dimension in systole (LVIDs) 
 Left ventricular internal dimension in diastole (LVIDd) 
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 Interventricular septal diameter in diastole (IVSd) 
 Left ventricular posterior wall thickness in diastole 
(LVPWd) 
 Ejection Fraction % (EF) 
o LV Mass 
o TR Jet velocity and gradient 
o Diastolic function indices 
 Isovolumic relaxation time (IVRT) 
 Mitral E Deceleration time (DT) 
 Mitral E and A velocities 
 
10. Conflicting interests : Nil 
 
11. Financial Supply  : Nil 
 
 Data were collected in a predetermined proforma (section 10) and 
later in Microsoft excel spreadsheet of a computer. 
 
Age and sex matched forty healthy subjects served as the control 
group.  
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12. Statistical analysis 
 Computer analysis of data was done using the software – 
Epidemiological Information Package, 2002 (Epi Info 2002) developed by the 
Centre for Disease Control and Prevention, Atlanta; U.S.A. for World Health 
Organisation. The range, median, standard deviation and statistical 
significance were calculated. Wherever p value was found to be less than 
0.05, it was considered significant. 
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Results  
The results of the present study are presented in the ensuing pages. 
 
Table 1 :   Age distribution 
 
Age (years) Alcoholic  
cirrhotics  
Non -  
alcoholic 
cirrhotics 
Total Controls 
20-40 3 (8%) 38 (56%) 41 (41%) 16 (40%) 
41-60 35 (92%) 24 (44%) 59 (59%) 24 (60%) 
Total 38 (38%) 62 (62%) 100 40 
 
 
• Out of the hundred patients selected, 38% were having alcoholic 
cirrhosis. 
 
• Most of the alcoholic cirrhotics were above the age of forty years 
while majority of non alcoholic cirrhotics in the study were young  
(< 40 years). 
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I. CIRRHOSIS ( N = 100 CASES) AND CONTROLS (n = 40) 
 
Table 2: LV Systolic Function Parameters (in cms) 
 
The LV systolic function parameters (LVIDs LVIDd, EF, IVSd, LVPWd) 
studied are presented in the table given below 
 
Parameter Type of cases Range Mean Std. 
Deviation 
P 
value 
a) Cirrhosis cases 2.51-4.35 3.19 0.48 LVIDs 
b) Controls 2.91-3.41 3.14 0.15 
0.683 
a) Cirrhosis cases 3.59-5.7 4.79 0.5 LVIDd 
b) Controls 4.13-5.22 4.71 0.35 
0.301 
a) Cirrhosis cases 50-86 67.66 8.67 EF (%) 
b) Controls 60-71 66.28 3.43 
0.1802 
a) Cirrhosis cases 0.45-1.4 0.86 0.19 IVSd 
b) Controls 0.67-1.04 0.89 0.09 
0.366 
a) Cirrhosis cases 0.5-1.9 0.88 0.25 LVPWd 
b) Controls 0.6-1.15 0.85 0.15 
0.9613 
 
When the left ventricular systolic function parameters were compared 
between cirrhosis patients and controls, there was no statistically significant 
difference. 
 
Table 3: PA systolic Pressure (PASP in mm Hg) 
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The PA systolic pressures of cirrhosis and controls are given in the following 
table 
 
Type of Cases Range Mean Std. Deviation 
Cirrhosis Cases 12.5-56 28.64 9.06 
Controls 13-29 20.4 4.21 
 
‘p’=0.0001 
There was significant difference between the PA systolic pressures of 
cirrhosis cases and controls. 
 
Table 4: LV Mass (in grams) 
 
The LV mass estimated in cirrhotics and controls are presented in the table 
given below 
 
Type of Cases Range Mean Std. Deviation 
Cirrhosis Cases 74-271 162.26 50.65 
Controls 90-210 159.33 41.77 
 
‘p’=0.8917 
The difference between LV Mass values of cirrhosis cases and controls 
were not statistically significant. 
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II. ALCOHOLIC CIRRHOSIS (A=38) AND NON-ALCOHOLIC 
CIRRHOSIS  (n=62) cases 
 
Table 5: LV Systolic function indices (in cms) 
 
LV systolic function indices (LVIDs, LVIDd, EF, IVSd, LVPWd) studied 
in alcoholic and non - alcoholic cirrhotic patients are presented in the tabular 
column below.   
 
Parameter Type of cases Range Mean Std. 
Deviation 
P 
value 
Alcoholic cirrhosis  2.56-4.35 3.25 0.58 LVIDs 
Non–alcoholic cirrhosis  2.51-4.1 3.17 0.41 
0.5938 
Alcoholic cirrhosis  3.59-5.7 4.77 0.55 LVIDd 
Non–alcoholic cirrhosis  4.04-5.6 4.81 0.48 
0.7596 
Alcoholic cirrhosis  50-81 65.42 8.94 EF (%) 
Non –alcoholic cirrhosis  52-86 69.03 8.23 
0.654 
Alcoholic cirrhosis  0.58-1.4 0.91 0.21 IVSd 
Non –alcoholic cirrhosis  0.45-1.12 0.84 0.17 
0.3701 
Alcoholic cirrhosis  0.54-1.21 0.89 0.19 0.2086 LVPWd 
Non –alcoholic cirrhosis  0.5-1.9 0.88 0.3 0.2026 
 
There was no statistically significant difference, when the LV systolic 
functions parameters were compared between alcoholic and non-alcoholic 
cirrhotics. 
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Table 6: PA Systolic Pressure (in mm Hg) 
 
PA systolic pressure measured in the alcoholic and non-alcoholic 
cirrhosis patients is tabulated below. 
 
Type of Cases Range Mean Std. Deviation 
Alcoholic Cirrhosis Cases 13.4-37.8 28.24 8.54 
Non Alcoholic Cirrhosis cases 12.5-56 28.88 9.42 
 
‘p’=0.9405 
 
Statistically significant difference does not exist between the PA 
systolic pressure values of alcoholic cirrhosis cases and Non alcoholic 
cirrhosis cases. 
Table 7: LV Mass (in grams) 
 
The estimated LV mass of alcoholic and non – alcoholic cirrhosis patients are 
listed below 
 
Type of Cases Range Mean Std. Deviation 
Alcoholic Cirrhosis Cases 74-262 175.5 57.4 
Non Alcoholic Cirrhosis cases 76-271 154.1 44.6 
 
‘p’=0.1148 
The difference between LV Mass values of Alcoholic cirrhosis cases 
and non alcoholic cirrhosis cases was not statistically significant. 
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III. ALCOHOLIC CIRRHOSIS (N=38) AND CONTROLS (N=40) 
 
Table 8: LV systolic function parameters (in cms) 
 
LV systolic function parameters (LVIDs, LVIDd, EF, IVSd, LVPWd) are 
compared between the alcoholic cirrhotics and controls in the following 
table.  
 
Parameter Type of cases Range Mean Std. 
Deviation 
P 
value 
Alcoholic cirrhosis 
cases 
2.56-4.35 3.25 0.58 LVIDs 
Controls 2.91-3.41 3.14 0.15 
0.4622 
Alcoholic cirrhosis 
cases 
3.59-5.7 4.77 0.55 LVIDd 
Controls 4.13-5.22 4.71 0.35 
0.2937 
Alcoholic cirrhosis 
cases 
50-81 65.42 8.94 EF (%) 
Controls 60-71 66.28 3.43 
0.7751 
Alcoholic cirrhosis 
cases 
0.58-1.4 0.91 0.21 IVSd 
Controls 0.67-1.04 0.89 0.09 
0.9322 
Alcoholic cirrhosis 
cases 
0.54-1.21 0.89 0.19 LVPWd 
Controls 0.6-1.15 0.85 0.15 
0.3813 
 
There was no significant difference between cirrhosis patients and 
controls when the LV systolic function parameters were compared. 
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Table 9: PA systolic pressure (in mm Hg) 
 
The PA systolic pressures calculated in the alcoholic cirrhotic patients 
and controls are furnished in the table given below. 
 
Type of Cases Range Mean Std. Deviation 
Alcoholic Cirrhosis Cases 13.4-46 28.24 8.54 
Controls 13-29 20.4 4.21 
 
‘p’=0.0001 
 
Statistically significant difference exists between the PA systolic 
pressure values of alcoholic cirrhosis cases and controls. 
 
Table 10: LV Mass (in grams) 
 
LV mass measurements of alcoholic cirrhosis cases and controls are 
compared below. 
 
Type of Cases Range Mean Std. Deviation 
Alcoholic Cirrhosis Cases 74-262 175.53 57.4 
Controls 90-210 159.33 41.77 
 
‘p’=0.3371 
 
The difference between LV Mass values of alcoholic cirrhosis cases 
and control cases was not statistically significant. 
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IV. NON – ALCOHOLIC CIRRHOSIS (N=62) CASES AND CONTROLS 
(N=40). 
 
Table 11: LV systolic function parameters (in cms) 
 
The LV systolic function parameters of non-alcoholic cirrhosis patients 
and controls are furnished in the table below. 
 
Parameter Type of cases Range Mean Std. 
Deviation 
P 
value 
Non -alcoholic cirrhosis cases 2.51-4.1 3.17 0.4 LVIDs 
Controls 2.91-3.41 3.14 0.15 
0.9181 
Non -alcoholic cirrhosis cases 4.04-5.6 4.81 0.48 LVIDd 
Controls 4.13-5.22 4.71 0.35 
0.4143 
Non-alcoholic cirrhosis cases 52-86 69.03 8.28 EF (%) 
Controls 60-71 66.28 3.43 
0.287 
Non-alcoholic cirrhosis cases 0.45-1.12 0.84 0.17 IVSd 
Controls 0.67-1.04 0.89 0.09 
0.0984 
Non-alcoholic cirrhosis cases 0.5-1.9 0.88 0.3 LVPWd 
Controls 0.6-1.15 0.85 0.15 
0.5014 
 
There was no statistically significant difference when the LV systolic 
function parameters were compared between non-alcoholic cirrhosis patients 
and controls. 
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Table 12: PA systolic pressure (in mm Hg) 
 
The PA systolic pressures calculated in non-alcoholic cirrhosis patients 
and controls are tabulated below. 
 
Type of Cases Range Mean Std. Deviation 
Non - Alcoholic Cirrhosis Cases 12.5-56 28.89 9.42 
Controls 13-29 20.4 4.21 
 
‘p’=0.0001 
 
There was statistically significant difference between the PA systolic 
pressure values of non-alcoholic cirrhosis cases and controls. 
 
Table 13: LV Mass (in grams) 
 
The LV mass measurements of non-alcoholic cirrhosis patients and 
controls are given in the table below. 
 
Type of Cases Range Mean Std. Deviation 
Non Alcoholic Cirrhosis Cases 76-271 154.1 44.6 
Controls 90-210 159.33 41.8 
 
‘p’=0.3895 
 
There is no statistically significant difference between LV mass values 
of non - alcoholic cirrhosis cases and controls. 
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Table 14 : Left Ventricular Diastolic Dysfunction patterns in 
cirrhosis patients 
 
The various diastolic dysfunction patterns which were noted are 
furnished in the following tabular column. 
 
Pattern of diastolic 
dysfunction 
Alcoholic 
cirrhosis 
patients 
(n=38) 
Non-alcoholic 
cirrhosis 
patients 
(n=62) 
Controls 
(n=40) 
Impaired relaxation pattern 13(34%) 15(24%) 6(15%) 
Pseudonormal pattern 4(11%) 7(11%) 2(5%) 
Restrictive pattern 2(5%) 7(11%) 2(5%) 
Total 19(50%) 29(46%) 10(25%) 
 
Majority of patients in both groups with diastolic dysfunction showed 
LV relaxation abnormally pattern (>50%) (Stage 1 diastolic dysfunction) 
 
I.  48 cirrhotic patients (48%) had diastolic dysfunction (DD) compared 
to 10 persons (25%) in the control group which was statistically 
significant (p<0.05)  
[The Standard Error of Difference (SED) was 8.47 while the Observed 
Difference (OD) was 23] 
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II. 19 patients (50%) of the alcohol cirrhotic had DD compared with 10 
(25%) individuals of controls which was significant (p<0.05)  
 [SED was 8.11while the OD was 25] 
 
III. 29 (46%) non-alcoholic cirrhosis patients had DD compared with 10 
(25%) individuals in the control group which was statistically 
significant (p<0.05)  
 [SED was 9.32 while the OD was 21] 
 
IV. 19 patients (50%) of alcoholic cirrhotics had DD compared with 29 
(46%) non-alcoholic cirrhotic patients which was not significant (p>1)  
 [SED was 10.28 while OD was only 4] 
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DISCUSSION 
 
 Cirrhosis of liver involves most organs and systems; hence it may be 
considered as a systemic disease48. Knowledge of cardiovascular system 
involvement in a cirrhotic patient is important in planning treatment and 
assessing the prognosis. Only a few studies have been done in India 
assessing the cardiac status of cirrhotic patients.  
 
 In this study, simple, non-invasive commonly available test, Colour 
Doppler Echocardiography was used as the main investigative modality to 
assess cardiac function. Procedures like cardiac catheterization are invasive, 
costly and available only in few selected centers. Hence it was not 
considered. 
 
 Only male patients were selected for the study since alcoholism and 
subsequently alcoholic cirrhosis are very rare in females. Both young and old 
patients with alcoholic and non – alcoholic cirrhosis were involved in the 
study. In order to assess the true effect of cirrhosis on cardiac functions, 
patients with common diseases affecting heart were excluded from the 
study. 
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 In cirrhosis, circulatory changes in the form of systemic vasodilation 
and a hyperdynamic state were previously reported2. This situation may 
produce an increase in stroke volume and subsequently cardiac output. This 
effect on the heart was studied in detail by assessing the M-mode 
echocardiographic left ventricular dimensions indicating the systolic functions 
of the heart. But this study showed no significant difference in the ejection 
fraction among patients and controls. Left ventricular chamber dimensions 
were comparable. 
 
 There was no significant difference in LV mass between cirrhosis and 
controls and between alcoholics and non alcoholics. This finding is different 
from an Indian study published by Pazhamalai et al49. This variation could be 
due to rigid criteria adopted in case selection. 
 
 A significant increase in the pulmonary artery systolic pressure (PASP) 
was seen cirrhotics compared to controls in the study. Hypoxemia, 
intrapulmonary shunting, portal – pulmonary shunting and increased levels 
of several vasoactive mediators and cytokines may be involved in the 
development of pulmonary hypertension. Pazhamalai et al49 also has 
reported a similar observation recently. 
 
The synthesis of L-carnitine is performed in the liver. So alteration in 
carnitine metabolism is expected in liver disease, especially in cirrhosis. 
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However studies estimating the levels of L-carnitine in cirrhosis patients 
showed conflicting results. Study by Selimoghn MA et al44 showed that 
children with cirrhosis have low plasma carnitine concentrations. Another 
study done in adults by Dr. Krahenbuhl S et al45 showed that cirrhotics are 
not carnitine deficient. There was a trend towards higher carnitine levels in 
alcoholic patients. This may result from increased carnitine biosynthesis 
because of increased skeletal muscle protein turnover in alcoholic cirrhosis 
patients. They also found that non – cirrhotic liver disease patients showed 
no change in plasma carnitine concentration. 
 
 Amodio P et al46 in their study found that there was significantly high 
levels of carnitine in cirrhotics independently of the aetiology of cirrhosis. 
They did not found any difference in values in the three Pugh – Child’s 
classes. They concluded that high levels of acetyl carnitine, short chain acyl 
carnitine, total esterified carnitine and total carnitine found in cirrhosis were 
linked to liver disease. Alcohol abuse may be only an exacerbating factor. 
 
 In a normal heart, during diastole, an initial active phase of relaxation 
and a later passive phase of filling are present. In the relaxation phase; a 
series of energy consuming steps occur which are mediated by hydrolysis of 
ATP2. In the latter filling phase, several complex interactions occur like 
diastolic suction, passive filling, pericardial restraint, ventricular interaction 
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and viscoelastic forces of the myocardium which determines the ‘effective 
operating left ventricular chamber compliance’2. 
 
 In the present study, left ventricular (LV) diastolic function was 
studied in depth using parameters like isovolumic relaxation time, mitral 
inflow velocity pattern and mitral E deceleration time. Cirrhosis patients 
showed an increased occurrence of diastolic dysfunction compared to 
controls. This finding was seen in both alcoholic and non - alcoholic patients. 
Majority of patients showed an impaired LV relaxation pattern indicating that 
the initial energy consuming step is being affected in cirrhosis. Similar 
observation was documented earlier by Alexander et al50 from Mumbai. 
 
 A few patients showed advanced diastolic dysfunction in the form of 
restrictive pattern. This usually occur when the passive stiffness of heart is 
affected by diffuse fibrosis or when the myocytes are hypertrophied. So , 
heart may also be influenced by growth factors which mediate fibrosis in 
liver. 
 
 However, there was no significant difference between the occurrence 
and pattern of diastolic dysfunction among alcoholic and non - alcoholic 
cirrhosis patients. 
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 Overall, the contributing factors for cardiac involvement in hepatic 
cirrhosis are summarized below: 
 
Table 15: Contributing factors for cardiac involvement  
in cirrhosis 
 
1. Circulatory changes 
2. Systemic vasodilatation 
3. Hyperdynamic circulation 
4. Vasoactive mediators 
5. Altered cardiac contractility 
 
 
Suggestions :- 
• Since cardiac involvement in cirrhosis is a relatively new area of 
work, it is suggested that more prospective studies need to be 
undertaken in a cohort of cirrhosis of various aetiologies to assess 
the extend of involvement in various stages of cirrhosis. 
 
• Future area of work 
 To investigate the therapeutic utility of cardio protective 
agents in minimizing or altering cardiac involvement in 
cirrhosis. 
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 More molecular researches need to be undertaken to 
delineate the underlying patho physiological 
mechanisms operating in the development of cirrhotic 
cardiomyopathy. 
 
Limitations of the study :- 
 In this part of the country, women alcoholics are a rarity. So to 
maintain homogeneity among the study population and controls, only men 
were considered. Hence the observations are limited to men only. 
 
 In view of the various interplaying mechanisms for the development 
of cardiac dysfunction in cirrhosis, and the observation that cardiac 
involvement worsens the hepatic functional status, there is a need to take 
up further works in these areas. 
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CONCLUSIONS 
 
1. Patients with alcoholic and non - alcoholic cirrhosis have higher 
occurrence of diastolic dysfunction (50% and 46% respectively) 
than controls which was statistically significant. This observation 
runs in parallel to other published data. 
 
2. Pulmonary artery systolic pressure was significantly increased in 
both alcoholic and non - alcoholic cirrhotics when compared with 
healthy controls. This finding was comparable with already 
published data. 
 
3. LV systolic function indices (LVIDs, LVIDd, IVSd, LVPWd and EF) 
were not altered in cirrhosis; be it alcoholic or non - alcoholic and 
it was not different for healthy controls statistically, in contrast to 
published observations. 
 
4. Variable observations noted in the present study may likely be 
related to the rigid criteria adopted in case selection and possibly 
due to genetic or ethnic difference as well as their susceptibility. 
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5. In view of the above conclusions, it is suggested to take up a 
prospective study with long term follow up with and without 
modern cardio protective agents in order to find out the effective 
interventions which minimize the progression of cirrhosis and 
subsequent cardiac dysfunction. 
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SUMMARY 
  
 Cirrhosis is a chronic liver disease with systemic complications. 
Cardiac involvement in cirrhosis is less studied and rarely reported. Here an 
attempt was made to design a prospective analytical observational study to 
find out the functional status of the heart in established alcoholic (n=32) 
and non - alcoholic (n=68) cirrhosis patients compared with asymptomatic 
healthy controls. Rigid criteria was adopted in the selection of cases in order 
to exclude co morbid conditions and other contributing factors. This study 
was confined among males as women alcoholics could not be identified in 
this area. The data was analysed statistically. 
 
 Left ventricular systolic function parameters (LVIDs, LVIDd, IVSd, 
LVPWd and ejection fraction) were comparable between alcoholics, non 
alcoholics and controls (p>0.05). 
 
 Pulmonary artery systolic pressure (PASP) in cirrhosis patients and 
controls ranged from 12.5 to 56 mm Hg and 13 to 29 mm Hg respectively. 
The mean among the two groups were 28.2+9.06 and 20.4+4.21 mm Hg 
respectively. The difference among cirrhotics and controls with reference to 
PASP were statistically highly significant (p=0.0001). 
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 The LV mass in cirrhotics patients and controls ranged from 74 to 271 
gms and 90 to 120 gms respectively. The mean among the two groups were 
162.26+50.65 and 159.33+41.77 grams respectively. But the difference was 
not statistically significant (p=0.8917). 
 
 48 cirrhotic patients (48%) had diastolic dysfunction compared to 10 
persons (25%) in the control group which was significant (p<0.05). This 
significance persisted in both alcoholic and non alcoholic groups. Majority of 
patients in both subsets of cirrhotic with diastolic dysfunction showed LV 
relaxation abnormality pattern. (68% in alcoholic and 52% in non alcoholic 
group respectively) 
 
 There was no significant difference in cardiac functions parameters 
when alcoholic cirrhotics were compared with non alcoholic cirrhotics 
(p>0.05). 
 
 The present study has brought out the pattern of cardiac involvement 
and the comparability of observations with published series. More molecular 
and clinical studies are required to design effective therapeutic measures to 
prevent the progression of cirrhosis and its systemic complications. 
 
 
 
MASTER  CHART 
 
Sl.No GROUP LVIDs LVIDd EF% IVSd LVPWd E/A RATIO DT IVRT 
PA 
sy.pr. 
LV 
mass 
1 ALCO. CIRRHO. 2.65 3.59 60 0.67 0.81 0.78 80 140 33.5 74 
2 ALCO. CIRRHO. 2.9 4.8 71 0.8 0.9 1.48 178 65 28 150 
3 ALCO. CIRRHO. 2.6 4.5 74 1.4 1.2 0.75 192 103 35.3 262 
4 ALCO. CIRRHO. 3.72 5.12 61 0.58 0.85 1.51 170 150 13.6 146 
5 ALCO. CIRRHO. 3.3 4.3 54 0.8 0.7 0.86 130 140 13.4 187.1 
6 ALCO. CIRRHO. 3.32 5.34 76 1.08 0.99 1.41 160 100 33 250 
7 ALCO. CIRRHO. 2.6 4.5 70 0.98 0.9 1.18 210 90 46 256 
8 ALCO. CIRRHO. 3.5 4.67 50 0.99 1.08 1.21 130 70 26 198 
9 ALCO. CIRRHO. 2.56 4.46 81 1.03 0.97 0.92 120 80 25 174.6 
10 ALCO. CIRRHO. 4.31 5.2 61 0.87 0.92 1.75 110 80 27.2 246.5 
11 ALCO. CIRRHO. 3.46 5.07 68 0.58 0.67 1.71 160 100 18.4 114.2 
12 ALCO. CIRRHO. 3.68 5.25 66 0.85 0.67 1.45 100 100 22 159.4 
13 ALCO. CIRRHO. 4.35 5.7 55 0.76 0.54 2.09 200 110 37.7 150.6 
14 ALCO. CIRRHO. 3.9 5.38 62 1.12 1.21 1.28 160 80 35.5 102.2 
15 ALCO. CIRRHO. 2.6 4.2 68 0.9 0.9 0.91 128 68 33.3 137 
16 ALCO. CIRRHO. 2.6 4.5 74 1.4 1.2 0.75 192 103 35.9 262 
17 ALCO. CIRRHO. 3.32 5.34 76 1.08 0.99 1.41 160 100 33 250 
18 ALCO. CIRRHO. 2.65 3.59 60 0.67 0.81 0.78 80 140 33.5 74 
19 ALCO. CIRRHO. 3.68 5.25 66 0.85 0.67 1.45 100 100 22 159.4 
20 ALCO. CIRRHO. 2.56 4.46 81 1.03 0.97 0.92 120 80 25 174.6 
21 ALCO. CIRRHO. 3.3 4.3 54 0.8 0.7 0.86 130 140 13.5 187.1 
22 ALCO. CIRRHO. 4.35 5.7 55 0.76 0.54 2.09 200 110 37.8 150.6 
23 ALCO. CIRRHO. 3.72 5.12 61 0.58 0.85 1.51 170 150 13.6 146 
24 ALCO. CIRRHO. 2.9 4.8 71 0.8 0.9 1.48 178 65 28 150 
25 ALCO. CIRRHO. 3.5 4.67 50 0.99 1.08 1.21 130 70 26 198 
26 ALCO. CIRRHO. 2.6 4.5 74 1.4 1.2 0.75 192 103 35.4 262 
Sl.No GROUP LVIDs LVIDd EF% IVSd LVPWd E/A RATIO DT IVRT 
PA 
sy.pr. 
LV 
mass 
27 ALCO. CIRRHO. 2.65 3.59 60 0.67 0.81 0.78 80 140 33.5 74 
28 ALCO. CIRRHO. 4.31 5.2 61 0.87 0.92 1.75 110 80 27.3 246.5 
29 ALCO. CIRRHO. 2.6 4.2 68 0.9 0.9 0.91 128 68 33.1 137 
30 ALCO. CIRRHO. 3.9 5.38 62 1.12 1.21 1.28 160 80 35 102.2 
31 ALCO. CIRRHO. 3.32 5.34 76 1.08 0.99 1.41 160 100 33 250 
32 ALCO. CIRRHO. 2.9 4.8 71 0.8 0.9 1.48 178 65 28 150 
33 ALCO. CIRRHO. 2.56 4.46 81 1.03 0.97 0.92 120 80 25 174.6 
34 ALCO. CIRRHO. 2.6 4.5 70 0.98 0.9 1.18 210 90 46 256 
35 ALCO. CIRRHO. 3.46 5.07 68 0.58 0.67 1.71 160 100 19 114.2 
36 ALCO. CIRRHO. 3.5 4.67 50 0.99 1.08 1.21 130 70 26 198 
37 ALCO. CIRRHO. 3.3 4.3 54 0.8 0.7 0.86 130 140 13.6 187.1 
38 ALCO. CIRRHO. 3.68 5.25 66 0.85 0.67 1.45 100 100 22 159.4 
39 NON ALCO. CIRRHO. 3 4.5 61 0.9 0.9 2.26 267 110 12.5 144 
40 NON ALCO. CIRRHO. 2.6 4.5 74 0.6 0.5 1.78 217 68 20.3 76 
41 NON ALCO. CIRRHO. 2.7 4.5 70.2 0.9 1.2 0.76 146 70 33.7 181 
42 NON ALCO. CIRRHO. 4.1 5.6 52 0.6 1.9 0.56 121 107 37 181 
43 NON ALCO. CIRRHO. 3.59 5.56 73 0.58 0.54 1.69 160 100 30 118.1 
44 NON ALCO. CIRRHO. 3.42 5.04 69 0.88 0.73 1.44 200 90 19.1 211 
45 NON ALCO. CIRRHO. 3.05 5.03 78 1.12 0.85 1.03 150 70 32 164.6 
46 NON ALCO. CIRRHO. 3.86 5.34 62 0.72 0.81 1.38 160 62 35 212.9 
47 NON ALCO. CIRRHO. 3.68 5.34 67 0.9 0.94 1.42 120 110 26 139 
48 NON ALCO. CIRRHO. 3.1 4.04 55 1.03 0.9 1 100 80 28 163.1 
49 NON ALCO. CIRRHO. 2.92 5.43 84 0.76 0.72 2.31 130 110 33 91 
50 NON ALCO. CIRRHO. 3.14 4.31 61 0.67 0.67 2.22 130 100 19.8 160.5 
51 NON ALCO. CIRRHO. 2.51 4.85 86 0.94 0.76 1.6 90 110 43.6 151.6 
52 NON ALCO. CIRRHO. 3.16 4.85 62 0.45 0.58 1.83 100 100 29.7 80 
53 NON ALCO. CIRRHO. 3.5 4.85 67 0.9 0.76 1.59 120 101.5 29.1 149.3 
54 NON ALCO. CIRRHO. 3.28 4.76 75 1.03 0.99 1.14 110 80 30.4 207 
55 NON ALCO. CIRRHO. 3.1 4.89 77 1.08 1.12 0.9 147 90 41 186 
Sl.No GROUP LVIDs LVIDd EF% IVSd LVPWd E/A RATIO DT IVRT 
PA 
sy.pr. 
LV 
mass 
56 NON ALCO. CIRRHO. 3.2 4.26 61 0.91 0.76 2.05 180 110 25.4 94 
57 NON ALCO. CIRRHO. 3.05 4.17 71 0.67 0.9 1.29 170 90 25 215 
58 NON ALCO. CIRRHO. 3.63 5.47 68 0.9 1.2 2 140 120 14.9 162 
59 NON ALCO. CIRRHO. 2.96 4.35 71 0.94 0.8 0.57 80 90 19 160 
60 NON ALCO. CIRRHO. 3.18 4.82 70 0.77 1.08 0.88 130 180 35 146 
61 NON ALCO. CIRRHO. 2.74 4.08 58 0.9 0.7 1.46 220 190 36 127 
62 NON ALCO. CIRRHO. 3 4.3 66 1 0.8 1.86 146 107 56 118 
63 NON ALCO. CIRRHO. 2.6 4.1 68 0.9 0.8 1.5 140 75 19 271 
64 NON ALCO. CIRRHO. 4.1 5.6 52 0.6 1.9 0.56 121 107 37 181 
65 NON ALCO. CIRRHO. 3.5 4.85 67 0.9 0.76 1.59 120 101.5 29.1 149.3 
66 NON ALCO. CIRRHO. 3.59 5.56 73 0.58 0.54 1.69 160 100 30 118.1 
67 NON ALCO. CIRRHO. 3.42 5.04 69 0.88 0.73 1.44 200 90 19.1 211 
68 NON ALCO. CIRRHO. 2.96 4.35 71 0.94 0.8 0.57 80 90 19 160 
69 NON ALCO. CIRRHO. 2.51 4.85 86 0.94 0.76 1.6 90 110 43.6 151.6 
70 NON ALCO. CIRRHO. 2.7 4.5 70.2 0.9 1.2 0.76 146 70 33.7 181 
71 NON ALCO. CIRRHO. 3.18 4.82 70 0.77 1.08 0.88 130 180 35 146 
72 NON ALCO. CIRRHO. 3 4.5 61 0.9 0.9 2.26 267 110 12.5 144 
73 NON ALCO. CIRRHO. 3.68 5.34 67 0.9 0.94 1.42 120 110 26 139 
74 NON ALCO. CIRRHO. 2.7 4.5 70.2 0.9 1.2 0.76 146 70 33.7 181 
75 NON ALCO. CIRRHO. 2.92 5.43 84 0.76 0.72 2.31 130 110 33 91 
76 NON ALCO. CIRRHO. 3.1 4.89 77 1.08 1.12 0.9 147 90 41 186 
77 NON ALCO. CIRRHO. 3.2 4.26 61 0.91 0.76 2.05 180 110 25.4 94 
78 NON ALCO. CIRRHO. 3.14 4.31 61 0.67 0.67 2.22 130 100 19.8 160.5 
79 NON ALCO. CIRRHO. 3.16 4.85 62 0.45 0.58 1.83 100 100 29.7 80 
80 NON ALCO. CIRRHO. 3.05 5.03 78 1.12 0.85 1.03 150 70 32 164.6 
81 NON ALCO. CIRRHO. 3.68 5.34 67 0.9 0.94 1.42 120 110 26 139 
82 NON ALCO. CIRRHO. 2.51 4.85 86 0.94 0.76 1.6 90 110 43.6 151.6 
83 NON ALCO. CIRRHO. 2.6 4.5 74 0.6 0.5 1.78 217 68 20.3 76 
84 NON ALCO. CIRRHO. 3.5 4.85 67 0.9 0.76 1.59 120 101.5 29.1 149.3 
Sl.No GROUP LVIDs LVIDd EF% IVSd LVPWd E/A RATIO DT IVRT 
PA 
sy.pr. 
LV 
mass 
85 NON ALCO. CIRRHO. 3.59 5.56 73 0.58 0.54 1.69 160 100 30 118.1 
86 NON ALCO. CIRRHO. 3 4.5 61 0.9 0.9 2.26 267 110 12.5 144 
87 NON ALCO. CIRRHO. 3.28 4.76 75 1.03 0.99 1.14 110 80 30.4 207 
88 NON ALCO. CIRRHO. 3.05 4.17 71 0.67 0.9 1.29 170 90 25 215 
89 NON ALCO. CIRRHO. 4.1 5.6 52 0.6 1.9 0.56 121 107 37 181 
90 NON ALCO. CIRRHO. 2.92 5.43 84 0.76 0.72 2.31 130 110 33 91 
91 NON ALCO. CIRRHO. 3.68 5.34 67 0.9 0.94 1.42 120 110 26 139 
92 NON ALCO. CIRRHO. 3 4.3 66 1 0.8 1.86 146 107 56 118 
93 NON ALCO. CIRRHO. 2.6 4.1 68 0.9 0.8 1.5 140 75 19 271 
94 NON ALCO. CIRRHO. 2.6 4.5 74 0.6 0.5 1.78 217 68 20.3 76 
95 NON ALCO. CIRRHO. 2.74 4.08 58 0.9 0.7 1.46 220 190 36 127 
96 NON ALCO. CIRRHO. 3.42 5.04 69 0.88 0.73 1.44 200 90 19.1 211 
97 NON ALCO. CIRRHO. 3.63 5.47 68 0.9 1.2 2 140 120 14.9 162 
98 NON ALCO. CIRRHO. 3.14 4.31 61 0.67 0.67 2.22 130 100 19.8 160.5 
99 NON ALCO. CIRRHO. 3.28 4.76 75 1.03 0.99 1.14 110 80 30.4 207 
100 NON ALCO. CIRRHO. 3.05 5.13 78 1.12 0.85 1.03 150 70 32 164.6 
101 CONTROL 3.26 5.17 69 0.91 0.96 1.3 208 99 29 208 
102 CONTROL 3.05 5.22 71 0.97 0.99 1.33 210 100 27 210 
103 CONTROL 3.13 4.34 63 0.85 0.72 0.97 202 63 17 99 
104 CONTROL 3.41 4.76 67 0.81 0.88 1.15 204 67 22 164 
105 CONTROL 3.29 4.79 69 0.89 0.91 1.21 203 66 24 170 
106 CONTROL 3.18 5.12 71 0.94 1.04 1.29 211 98 23 204 
107 CONTROL 2.92 4.13 60 0.8 0.62 0.91 198 60 14 98 
108 CONTROL 3.37 4.87 65 0.95 0.82 1.21 203 81 22 176 
109 CONTROL 3.04 5.09 69 0.99 0.93 1.29 199 95 21 199 
110 CONTROL 2.99 4.34 66 0.86 0.77 1.04 200 84 18 164 
111 CONTROL 2.94 4.27 63 0.81 0.61 0.97 201 64 15 109 
112 CONTROL 3.33 4.98 71 1.01 0.91 1.13 207 91 26 188 
113 CONTROL 3.09 4.63 66 0.95 0.84 1.05 205 88 22 177 
Sl.No GROUP LVIDs LVIDd EF% IVSd LVPWd E/A RATIO DT IVRT 
PA 
sy.pr. 
LV 
mass 
114 CONTROL 2.99 4.39 64 0.91 0.73 0.96 199 65 19 134 
115 CONTROL 2.91 4.17 60 0.72 0.6 0.89 197 60 14 94 
116 CONTROL 3.14 4.75 67 0.84 0.87 0.9 201 77 19 175 
117 CONTROL 3.39 5.04 70 0.97 0.99 0.97 205 92 17 182 
118 CONTROL 3.11 4.57 66 0.89 0.86 0.91 203 87 23 134 
119 CONTROL 3.24 4.79 69 0.94 0.92 0.94 205 91 28 141 
120 CONTROL 3.07 4.19 62 0.87 0.63 0.9 198 59 15 91 
121 CONTROL 3.16 4.43 65 0.92 0.69 0.99 200 71 19 98 
122 CONTROL 3.33 4.72 68 0.98 0.86 1.17 204 69 13 145 
123 CONTROL 2.95 4.21 65 0.8 0.65 1.01 199 62 15 96 
124 CONTROL 2.91 4.18 61 0.67 0.6 0.91 198 60 14 90 
125 CONTROL 2.99 4.33 65 0.71 0.62 1.05 201 67 17 101 
126 CONTROL 3.1 4.65 67 0.82 0.83 1.22 204 74 21 153 
127 CONTROL 3.32 4.99 71 0.96 0.96 1.3 206 86 17 179 
128 CONTROL 3.15 4.86 67 0.91 0.92 1.27 204 87 25 182 
129 CONTROL 2.96 4.41 60 0.85 0.84 1.16 202 67 19 131 
130 CONTROL 3.03 4.49 62 0.77 0.87 1.14 202 65 19 135 
131 CONTROL 3.14 4.88 68 0.79 0.93 1.22 205 79 23 1877 
132 CONTROL 3.37 5.07 67 0.94 1.02 1.31 206 99 19 194 
133 CONTROL 3.09 5.17 71 1.01 1.12 1.34 209 100 20 208 
134 CONTROL 3.12 4.76 65 0.91 0.86 1.09 201 73 27 201 
135 CONTROL 3.22 4.93 66 0.89 0.94 1.22 202 88 24 197 
136 CONTROL 2.99 4.34 60 0.71 0.69 1.19 199 62 21 126 
137 CONTROL 3.38 5.18 71 0.99 1.03 1.31 210 98 22 208 
138 CONTROL 3.28 5.22 70 1.02 1.15 1.34 211 99 21 210 
139 CONTROL 3.07 5.01 68 1.04 0.97 1.29 210 97 19 209 
140 CONTROL 3.19 5.04 66 0.94 0.94 1.27 209 94 26 206 
 
Figure 13: Pattern of Diastolic dysfunction 
(DD) in Alcoholic cirrhosis patients
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Figure 14: Pattern of Diastolic dysfunction 
(DD) in Non - alcoholic cirrhosis patients
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Figure 4: Age distribution of patients in the study
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Figure 5: Comparison of PASP 
between cirrhotics and controls
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Figure 6: Comparison of LV mass between 
cirrhotics and controls
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Figure 7: Comparison of PASP between alcoholic and 
non alcoholic cirrhosis patients
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Figure 8: Comparison of LV Mass between alcoholic 
and non alcoholic cirrhosis patients
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Figure 9: Comparison of PASP between alcoholic 
cirrhosis cases and controls
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Figure 10: Comparison of LV Mass between 
alcoholic cirrhosis cases and controls
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Figure 11: Comparison of PASP between non –
alcoholic cirrhotics and controls
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Figure 12: Comparison of LV Mass between non –
alcoholic cirrhotics and controls
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